ACS chemical neuroscience molecule spotlight on valdoxen

Corey R. Hopkins

doi:10.1021/cn100062j

ACS chemical neuroscience molecule spotlight on valdoxen

Corey R. Hopkins

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT_2C receptor.

Original language	English (US)
Pages (from-to)	772-773
Number of pages	2
Journal	ACS Chemical Neuroscience
Volume	1
Issue number	12
DOIs	https://doi.org/10.1021/cn100062j
State	Published - Dec 15 2010
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

Access to Document

10.1021/cn100062j

Fingerprint Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on valdoxen'. Together they form a unique fingerprint.

Cite this

Hopkins, C. R. (2010). ACS chemical neuroscience molecule spotlight on valdoxen. ACS Chemical Neuroscience, 1(12), 772-773. https://doi.org/10.1021/cn100062j

@article{7212c976f5954849b2acf45baf8e4522,

title = "ACS chemical neuroscience molecule spotlight on valdoxen",

abstract = "A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT2C receptor.",

author = "Hopkins, {Corey R.}",

year = "2010",

month = dec,

day = "15",

doi = "10.1021/cn100062j",

language = "English (US)",

volume = "1",

pages = "772--773",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "12",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on valdoxen

AU - Hopkins, Corey R.

PY - 2010/12/15

Y1 - 2010/12/15

N2 - A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT2C receptor.

AB - A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT2C receptor.

UR - http://www.scopus.com/inward/record.url?scp=78650322868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650322868&partnerID=8YFLogxK

U2 - 10.1021/cn100062j

DO - 10.1021/cn100062j

M3 - Article

C2 - 22778814

AN - SCOPUS:78650322868

VL - 1

SP - 772

EP - 773

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 12

ER -